Title: Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.
Journal: Neurobiology of disease 20161201
Title: Getting personal: Endogenous adenosine receptor signaling in lymphoblastoid cell lines.
Journal: Biochemical pharmacology 20160901
Title: Adenosine A2A receptor as a drug discovery target.
Journal: Journal of medicinal chemistry 20140508
Title: 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Journal: Bioorganic & medicinal chemistry 20131201
Title: Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease.
Journal: Journal of clinical pharmacology 20121001
Title: Design and synthesis of 8-substituted benzamido-phenylxanthine derivatives as MAO-B inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20120215
Title: Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.
Journal: Parkinsonism & related disorders 20120201
Title: Istradefylline for the treatment of Parkinson's disease.
Journal: Expert opinion on pharmacotherapy 20120101
Title: Functional changes in postsynaptic adenosine A(2A) receptors during early stages of a rat model of Huntington disease.
Journal: Experimental neurology 20111101
Title: An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Journal: Fundamental & clinical pharmacology 20111001
Title: Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones.
Journal: European journal of medicinal chemistry 20110901
Title: An update on adenosine A2A receptors as drug target in Parkinson's disease.
Journal: CNS & neurological disorders drug targets 20110901
Title: Biophysical mapping of the adenosine A2A receptor.
Journal: Journal of medicinal chemistry 20110714
Title: Re: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Journal: Journal of clinical pharmacology 20110501
Title: Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.
Journal: Expert opinion on drug metabolism & toxicology 20110401
Title: International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.
Journal: Pharmacological reviews 20110301
Title: Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.
Journal: Journal of medicinal chemistry 20110210
Title: Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease.
Journal: Journal of clinical pharmacology 20110101
Title: In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
Journal: Journal of medicinal chemistry 20101125
Title: An efficient route to xanthine based A(2A) adenosine receptor antagonists and functional derivatives.
Journal: Organic & biomolecular chemistry 20100921
Title: Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists.
Journal: Bioorganic & medicinal chemistry letters 20100901
Title: Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.
Journal: Movement disorders : official journal of the Movement Disorder Society 20100730
Title: A long-term study of istradefylline in subjects with fluctuating Parkinson's disease.
Journal: Parkinsonism & related disorders 20100701
Title: Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.
Journal: Parkinsonism & related disorders 20100101
Title: Caffeine and an adenosine A(2A) receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life.
Journal: Journal of neurochemistry 20100101
Title: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Journal: Journal of clinical pharmacology 20091201
Title: Effects of the adenosine A 2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide.
Journal: Neuroscience 20090929
Title: Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism.
Journal: Behavioural brain research 20090719
Title: Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
Journal: Parkinsonism & related disorders 20090701
Title: Histone H3 phosphorylation is under the opposite tonic control of dopamine D2 and adenosine A2A receptors in striatopallidal neurons.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090601
Title: Antagonists of the human A(2A) receptor. Part 5: Highly bio-available pyrimidine-4-carboxamides.
Journal: Bioorganic & medicinal chemistry letters 20090515
Title: Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines.
Journal: Journal of medicinal chemistry 20090108
Title: Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Journal: Movement disorders : official journal of the Movement Disorder Society 20081115
Title: The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
Journal: Psychopharmacology 20081001
Title: Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.
Journal: Bioorganic & medicinal chemistry 20080915
Title: A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.
Journal: Journal of clinical pharmacology 20080901
Title: Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain.
Journal: Synapse (New York, N.Y.) 20080901
Title: A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
Journal: Neurology 20080603
Title: Inflammation in Parkinson's disease: an update.
Journal: Current opinion in investigational drugs (London, England : 2000) 20080501
Title: Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism.
Journal: Frontiers in bioscience : a journal and virtual library 20080501
Title: Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801.
Journal: Experimental neurology 20080401
Title: A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs.
Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience 20080319
Title: Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms.
Journal: Annals of neurology 20080301
Title: Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces 'off' time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
Journal: Annals of neurology 20080301
Title: Parkinson's Disease and Related Disorders--XVIIth WFN world congress.
Journal: IDrugs : the investigational drugs journal 20080301
Title: Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?
Journal: Annals of neurology 20080301
Title: Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.
Journal: Journal of medicinal chemistry 20080214
Title: Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol.
Journal: Neuropharmacology 20080101
Title: The effect of caffeine to increase reaction time in the rat during a test of attention is mediated through antagonism of adenosine A2A receptors.
Journal: Behavioural brain research 20071211
Title: Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: structure-activity relationships as adenosine A(1) and A(2A) receptor ligands.
Journal: Bioorganic & medicinal chemistry 20071115
Title: N9-benzyl-substituted 1,3-dimethyl- and 1,3-dipropyl-pyrimido[2,1-f]purinediones: synthesis and structure-activity relationships at adenosine A1 and A2A receptors.
Journal: Bioorganic & medicinal chemistry 20070715
Title: The effect of striatal dopamine depletion and the adenosine A2A antagonist KW-6002 on reversal learning in rats.
Journal: Neurobiology of learning and memory 20070701
Title: Amphetamine and the adenosine A(2A) antagonist KW-6002 enhance the effects of conditional temporal probability of a stimulus in rats.
Journal: Behavioral neuroscience 20070601
Title: Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.
Journal: Naunyn-Schmiedeberg's archives of pharmacology 20070401
Title: 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists.
Journal: Journal of medicinal chemistry 20070222
Title: Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.
Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience 20061227
Title: Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Journal: Journal of the neurological sciences 20061025
Title: Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases.
Journal: Expert opinion on investigational drugs 20060801
Title: Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors.
Journal: Journal of neurochemistry 20060101
Title: The effect of the adenosine A(2A) antagonist KW-6002 on motor and motivational processes in the rat.
Journal: Psychopharmacology 20060101
Title: Effects of the A 2A adenosine receptor antagonist KW6002 in the nucleus accumbens in vitro and in vivo.
Journal: Pharmacology, biochemistry, and behavior 20060101
Title: New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
Journal: Life sciences 20051112
Title: Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice.
Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience 20051109
Title: 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
Journal: Journal of medicinal chemistry 20051103
Title: Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Journal: Experimental neurology 20050701
Title: Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
Journal: Expert opinion on investigational drugs 20050601
Title: Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.
Journal: Pharmacology & therapeutics 20050301
Title: KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse.
Journal: Neuropharmacology 20050301
Title: Other pharmacological treatments for motor complications and dyskinesias.
Journal: Movement disorders : official journal of the Movement Disorder Society 20050101
Title: Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.
Journal: Drugs & aging 20050101
Title: Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease.
Journal: The Journal of organic chemistry 20040514
Title: Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
Journal: Neuroscience 20040101
Title: A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD.
Journal: Neurology 20031209
Title: A2A receptors in neuroprotection of dopaminergic neurons.
Journal: Neurology 20031209
Title: Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists.
Journal: Neurology 20031209
Title: Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Journal: Neurology 20031209
Title: Adenosine A2A receptors and depression.
Journal: Neurology 20031209
Title: Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Journal: Neurology 20031209
Title: Translating A2A antagonist KW6002 from animal models to parkinsonian patients.
Journal: Neurology 20031209
Title: A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Journal: Experimental neurology 20031101
Title: Nondopaminergic symptomatic therapies for Parkinson's disease: turn on or turn off?
Journal: Neurology 20030812
Title: Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
Journal: Neurology 20030812
Title: Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
Journal: Neurology 20030812
Title: Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes.
Journal: Glia 20030801
Title: Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.
Journal: Bioorganic & medicinal chemistry 20030403
Title: Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
Journal: Journal of neurochemistry 20030301
Title: Distribution of adenosine A(2A) receptor antagonist KW-6002 and its effect on gene expression in the rat brain.
Journal: Brain research 20021025
Title: [The treatment of Parkinson's disease--adenosine A2A receptor antagonists].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20020101
Title: Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.
Journal: Journal of neurochemistry 20020101
Title: Evaluation of [4-O-methyl-(11)C]KW-6002 as a potential PET ligand for mapping central adenosine A(2A) receptors in rats.
Journal: Synapse (New York, N.Y.) 20011201
Title: Solubilisation and immunoprecipitation of rat striatal adenosine A(2A) receptors.
Journal: European journal of pharmacology 20011116
Title: Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease.
Journal: Neurotoxicity research 20011101
Title: Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice.
Journal: British journal of pharmacology 20010901
Title: Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience 20010515
Title: KW-6002 (Kyowa Hakko Kogyo).
Journal: Current opinion in investigational drugs (London, England : 2000) 20010501
Title: Selective adenosine A2A receptor antagonists.
Journal: Farmaco (Societa chimica italiana : 1989) 20010101
Title: Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Journal: Experimental neurology 20000401
Title: Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
Journal: Psychopharmacology 19991101
Title: Chen JF, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001 May 15;21(10):RC143.
Title: Shiozaki S, et al. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl). 1999 Nov;147(1):90-5.
Title: Kanda T, et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000 Apr;162(2):321-7.
Title: Brambilla R, et al. Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia. 2003 Aug;43(2):190-4.
Title: Mihara T, et al. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5--amino-3-(4-fluorophenyl)pyrazin-2-yl-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition. J Pharm
